Taj Oncology Drug Pipeline & Cancer Clinical Trials

Taj Pharma Oncology Plant is committed to discovering, investigating, and developing affordable generic bio-similar of first generic alternative for cancer therapies that improve the outlook for cancer patients worldwide.

Taj Pharma’s strong pipeline—one of the most robust in the India Generics industry—includes immunotherapies and bio-similars, and is centered on exploring a wide array of approaches across many tumor types. Taj Pharma aims to develop the most innovative generic alternatives of originator medicines that will help life span of cancer patients.

Generic NameDosageStrength
OsimertinibTablet80Non-small-cell lung carcinomas
PalbociclibCapsule125HR+ and HER2- Breast cancer
TucatinibTablet150HER2-positive Breast cancer
TemozolomideCapsule20Brain cancer
TemozolomideCapsule100Brain cancer
DasatinibTablet70Chronic myelogenous leukemia and acute lymphoblastic leukemia
DasatinibTablet100Chronic myelogenous leukemia and acute lymphoblastic leukemia
DasatinibTablet140Chronic myelogenous leukemia and acute lymphoblastic leukemia
PazopanibTablet200Advanced renal cell carcinoma,
advanced soft tissue sarcoma